A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (NCT05645692)
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Who can join: Review the eligibility criteria below.
Location: Cleveland Clinic — Cleveland, Ohio
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (56 Sites)
Showing the first 25 of 56 sites.
- Cleveland Clinic — Cleveland, Ohio
- MD Anderson Cancer Center — Houston, Texas
- Macquarie University Hospital — Macquarie Park, New South Wales
- Lyell McEwin Hospital — Adelaide, South Australia
- ICON Cancer Care Adelaide — Kurralta Park, South Australia
- Hospital Universitario Evangelico De Curitiba — Curitiba, Paraná
- Hospital das Clinicas - UFRGS — Porto Alegre, Rio Grande do Sul
- Hospital de Amor Amazônia — Porto Velho, Rondônia
- *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia — Santo André, São Paulo
- Hospital Alemao Oswaldo Cruz — São Paulo, São Paulo
- Beijing Cancer Hospital — Beijing,
- West China Hospital - Sichuan University — Chengdu,
- Sun yat-sen University Cancer Center — Guangzhou,
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine — Shanghai,
- Aarhus Universitetshospital — Aarhus N,
- Herlev Hospital — Herlev,
- Centre Leon Berard — Lyon,
- Gustave Roussy — Villejuif,
- Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie — Halle,
- Martini-Klinik am UKE GmbH — Hamburg,
- Alexandras General Hospital of Athens — Athens,
- Attikon University General Hospital — Chaïdári,
- Theageneio Hospital — Thessaloniki,
- A.O. Universitaria Ospedale Consorziale Policlinico Di Bari — Bari, Apulia
- Istituto Nazionale Tumori Irccs Fondazione G. Pascale — Naples, Campania
📞 Contact the Study Coordinator
Phone: (866) 223-8100
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Cancer
- Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
- A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
- A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
- Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Los Angeles, California
Explore by condition: All Urothelial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.